Do Direct Deposit Loans Help to Pick out My Best Finance?

Yes, you have an opportunity to choose your best finance with direct deposit loans…

Harrow Health P/E ratio is -71.31. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Harrow Health’s P/E ratio What is Harrow Health P/E Ratio? Harrow Health’s P/E ratio is -71.31, which represents a 184.56% decrease from the same period last year. their 1-year average P / E ratio is -23.44 and their 5-year average is -0.51. What is Harrow Health Net EPS? Harrow Health’s net earnings for the most recent quarter were -0.1$, which represents a 137.04% decrease over the same period last year. Who are Harrow Health Competitors? Based on Jika.io AI model, Adamis Pharmaceuticals, Avadel Pharmaceuticals, Biofrontera AG, Kamada, Paion AG, ProPhase Labs, TherapeuticsMD, Zynerba Pharmaceuticals are considered to be Harrow Health’s competitors because the companies operate within the same industry as Harrow Health and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Harrow Health. Who is Harrow Health’s Biggest competitor? Harrow Health’s biggest competitor is Adamis Pharmaceuticals, based on the Jika.io AI model. it has a similar market capitalization to Harrow Health in the industry, it dominates a similar share of the market as Harrow Health, and it provides and markets very similar services. What industry is Harrow Health in? Harrow Health is part of the Pharmaceutical Manufacturers – Special & Generic Industry and the Healthcare sector. Harrow Health vs Adamis Pharmaceuticals Market Cap: Harrow Health’s Market Cap of 189217696 is higher than Adamis Pharmaceuticals Market Cap of 79029080. Average Volume: Harrow Health’s Average Volume of 128163.0 is lower than Adamis Pharmaceuticals Average Volume of 670008.0. Beta: Harrow Health’s Beta of 0.9 is lower than Adamis Pharmaceuticals Beta of 1.27. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Adamis Pharmaceuticals Revenue of 6.217M. Net Income: Harrow Health’s Net Income of -17741.0 is higher than Adamis Pharmaceuticals Net Income of -11.361M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is lower than Adamis Pharmaceuticals Gross Profit of 596232.0. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Adamis Pharmaceuticals Ebitda of -9.788M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is higher than Adamis Pharmaceuticals P/E Ratio of -2.54. P/S Ratio: Harrow Health’s P/S Ratio of 28.24 is higher than Adamis Pharmaceuticals P/S Ratio of 10.71. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is lower than Adamis Pharmaceuticals P/B Ratio of 4.97. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Adamis Pharmaceuticals P/FCF Ratio of -1.98. ROE: Harrow Health’s ROE of -0.21 is lower than Adamis Pharmaceuticals ROE of -1.01. ROA: Harrow Health’s ROA of -0.03 is lower than Adamis Pharmaceuticals ROA of -1.02. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Adamis Pharmaceuticals Return On Capital Employed of -2.08. Gross Profit Margin: Harrow Health’s Gross Profit Margin of 0.67 is higher than Adamis Pharmaceuticals Gross Profit Margin of 0.04. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Adamis Pharmaceuticals Assets (Total) of 38.298M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Adamis Pharmaceuticals Debt (Total) of 0.0. Harrow Health vs Avadel Pharmaceuticals Market Cap: Harrow Health’s Market Cap of 189217696 is lower than Avadel Pharmaceuticals Market Cap of 216079824. Average Volume: Harrow Health’s Average Volume of 128163.0 is lower than Avadel Pharmaceuticals Average Volume of 4.203M. Beta: Harrow Health’s Beta of 0.9 is lower than Avadel Pharmaceuticals Beta of 1.17. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Avadel Pharmaceuticals Revenue of 0.0. Net Income: Harrow Health’s Net Income of -17741.0 is lower than Avadel Pharmaceuticals Net Income of -77.329M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is higher than Avadel Pharmaceuticals Gross Profit of 0.0. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Avadel Pharmaceuticals Ebitda of -85.546M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is higher than Avadel Pharmaceuticals P/E Ratio of -2.38. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is lower than Avadel Pharmaceuticals P/B Ratio of 3.9. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Avadel Pharmaceuticals P/FCF Ratio of -3.29. ROE: Harrow Health’s ROE of -0.21 is lower than Avadel Pharmaceuticals ROE of -1.03. ROA: Harrow Health’s ROA of -0.03 is lower than Avadel Pharmaceuticals ROA of -0.41. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Avadel Pharmaceuticals Return On Capital Employed of -0.56. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Avadel Pharmaceuticals Assets (Total) of 247.265M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Avadel Pharmaceuticals Debt (Total) of 145.004M. Shareholders Equity: Harrow Health’s Shareholders Equity of 10931.0 is lower than Avadel Pharmaceuticals Shareholders Equity of 78.244M. Harrow Health vs Biofrontera AG Market Cap: Harrow Health’s Market Cap of 189217696 is higher than Biofrontera AG Market Cap of 67210112. Average Volume: Harrow Health’s Average Volume of 128163.0 is higher than Biofrontera AG Average Volume of 11606.0. Beta: Harrow Health’s Beta of 0.9 is lower than Biofrontera AG Beta of 1.54. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Biofrontera AG Revenue of 30.346M. Net Income: Harrow Health’s Net Income of -17741.0 is higher than Biofrontera AG Net Income of -13.023M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is higher than Biofrontera AG Gross Profit of 26.81M. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Biofrontera AG Ebitda of -4.284M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is lower than Biofrontera AG P/E Ratio of 4.42. P/S Ratio: Harrow Health’s P/S Ratio of 28.24 is higher than Biofrontera AG P/S Ratio of 2.4. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is lower than Biofrontera AG P/B Ratio of 4.23. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Biofrontera AG P/FCF Ratio of -5.53. ROE: Harrow Health’s ROE of -0.21 is lower than Biofrontera AG ROE of -0.95. ROA: Harrow Health’s ROA of -0.03 is lower than Biofrontera AG ROA of -0.24. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Biofrontera AG Return On Capital Employed of -0.32. Gross Profit Margin: Harrow Health’s Gross Profit Margin of 0.67 is lower than Biofrontera AG Gross Profit Margin of 0.87. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Biofrontera AG Assets (Total) of 56.39M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Biofrontera AG Debt (Total) of 23.875M. Harrow Health vs Kamada Market Cap: Harrow Health’s Market Cap of 189217696 is lower than Kamada Market Cap of 209666336. Average Volume: Harrow Health’s Average Volume of 128163.0 is lower than Kamada Average Volume of 15760.0. Beta: Harrow Health’s Beta of 0.9 is higher than Kamada Beta of 0.23. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Kamada Revenue of 103.642M. Net Income: Harrow Health’s Net Income of -17741.0 is lower than Kamada Net Income of -2.23M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is higher than Kamada Gross Profit of 30.328M. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Kamada Ebitda of 5.001M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is higher than Kamada P/E Ratio of -31.71. P/S Ratio: Harrow Health’s P/S Ratio of 28.24 is higher than Kamada P/S Ratio of 2.0. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is higher than Kamada P/B Ratio of 1.22. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Kamada P/FCF Ratio of -22.35. ROE: Harrow Health’s ROE of -0.21 is higher than Kamada ROE of -0.04. ROA: Harrow Health’s ROA of -0.03 is higher than Kamada ROA of -0.02. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Kamada Return On Capital Employed of -0.01. Gross Profit Margin: Harrow Health’s Gross Profit Margin of 0.67 is higher than Kamada Gross Profit Margin of 0.31. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Kamada Assets (Total) of 318.667M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Kamada Debt (Total) of 42.338M. Shareholders Equity: Harrow Health’s Shareholders Equity of 10931.0 is lower than Kamada Shareholders Equity of 176.824M. About Harrow Health Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. the company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business, and DEXYCU, a treatment for post-operative inflammation. the company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of proprietary non-intravenous, sedative and anesthesia therapeutics for human medical procedures in hospital, outpatient and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company engaged in developing and commercialization of drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was previously known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 2006 and has its headquarters in San Diego, California.">Harrow Health Stock – is a Buy, Sell or Hold?The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Harrow Health P/E ratio is -71.31. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Harrow Health’s P/E ratio What is Harrow Health P/E Ratio? Harrow Health’s P/E ratio is -71.31, which represents a 184.56% decrease from the same period last year. their 1-year average P / E ratio is -23.44 and their 5-year average is -0.51. What is Harrow Health Net EPS? Harrow Health’s net earnings for the most recent quarter were -0.1$, which represents a 137.04% decrease over the same period last year. Who are Harrow Health Competitors? Based on Jika.io AI model, Adamis Pharmaceuticals, Avadel Pharmaceuticals, Biofrontera AG, Kamada, Paion AG, ProPhase Labs, TherapeuticsMD, Zynerba Pharmaceuticals are considered to be Harrow Health’s competitors because the companies operate within the same industry as Harrow Health and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Harrow Health. Who is Harrow Health’s Biggest competitor? Harrow Health’s biggest competitor is Adamis Pharmaceuticals, based on the Jika.io AI model. it has a similar market capitalization to Harrow Health in the industry, it dominates a similar share of the market as Harrow Health, and it provides and markets very similar services. What industry is Harrow Health in? Harrow Health is part of the Pharmaceutical Manufacturers – Special & Generic Industry and the Healthcare sector. Harrow Health vs Adamis Pharmaceuticals Market Cap: Harrow Health’s Market Cap of 189217696 is higher than Adamis Pharmaceuticals Market Cap of 79029080. Average Volume: Harrow Health’s Average Volume of 128163.0 is lower than Adamis Pharmaceuticals Average Volume of 670008.0. Beta: Harrow Health’s Beta of 0.9 is lower than Adamis Pharmaceuticals Beta of 1.27. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Adamis Pharmaceuticals Revenue of 6.217M. Net Income: Harrow Health’s Net Income of -17741.0 is higher than Adamis Pharmaceuticals Net Income of -11.361M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is lower than Adamis Pharmaceuticals Gross Profit of 596232.0. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Adamis Pharmaceuticals Ebitda of -9.788M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is higher than Adamis Pharmaceuticals P/E Ratio of -2.54. P/S Ratio: Harrow Health’s P/S Ratio of 28.24 is higher than Adamis Pharmaceuticals P/S Ratio of 10.71. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is lower than Adamis Pharmaceuticals P/B Ratio of 4.97. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Adamis Pharmaceuticals P/FCF Ratio of -1.98. ROE: Harrow Health’s ROE of -0.21 is lower than Adamis Pharmaceuticals ROE of -1.01. ROA: Harrow Health’s ROA of -0.03 is lower than Adamis Pharmaceuticals ROA of -1.02. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Adamis Pharmaceuticals Return On Capital Employed of -2.08. Gross Profit Margin: Harrow Health’s Gross Profit Margin of 0.67 is higher than Adamis Pharmaceuticals Gross Profit Margin of 0.04. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Adamis Pharmaceuticals Assets (Total) of 38.298M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Adamis Pharmaceuticals Debt (Total) of 0.0. Harrow Health vs Avadel Pharmaceuticals Market Cap: Harrow Health’s Market Cap of 189217696 is lower than Avadel Pharmaceuticals Market Cap of 216079824. Average Volume: Harrow Health’s Average Volume of 128163.0 is lower than Avadel Pharmaceuticals Average Volume of 4.203M. Beta: Harrow Health’s Beta of 0.9 is lower than Avadel Pharmaceuticals Beta of 1.17. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Avadel Pharmaceuticals Revenue of 0.0. Net Income: Harrow Health’s Net Income of -17741.0 is lower than Avadel Pharmaceuticals Net Income of -77.329M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is higher than Avadel Pharmaceuticals Gross Profit of 0.0. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Avadel Pharmaceuticals Ebitda of -85.546M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is higher than Avadel Pharmaceuticals P/E Ratio of -2.38. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is lower than Avadel Pharmaceuticals P/B Ratio of 3.9. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Avadel Pharmaceuticals P/FCF Ratio of -3.29. ROE: Harrow Health’s ROE of -0.21 is lower than Avadel Pharmaceuticals ROE of -1.03. ROA: Harrow Health’s ROA of -0.03 is lower than Avadel Pharmaceuticals ROA of -0.41. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Avadel Pharmaceuticals Return On Capital Employed of -0.56. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Avadel Pharmaceuticals Assets (Total) of 247.265M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Avadel Pharmaceuticals Debt (Total) of 145.004M. Shareholders Equity: Harrow Health’s Shareholders Equity of 10931.0 is lower than Avadel Pharmaceuticals Shareholders Equity of 78.244M. Harrow Health vs Biofrontera AG Market Cap: Harrow Health’s Market Cap of 189217696 is higher than Biofrontera AG Market Cap of 67210112. Average Volume: Harrow Health’s Average Volume of 128163.0 is higher than Biofrontera AG Average Volume of 11606.0. Beta: Harrow Health’s Beta of 0.9 is lower than Biofrontera AG Beta of 1.54. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Biofrontera AG Revenue of 30.346M. Net Income: Harrow Health’s Net Income of -17741.0 is higher than Biofrontera AG Net Income of -13.023M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is higher than Biofrontera AG Gross Profit of 26.81M. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Biofrontera AG Ebitda of -4.284M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is lower than Biofrontera AG P/E Ratio of 4.42. P/S Ratio: Harrow Health’s P/S Ratio of 28.24 is higher than Biofrontera AG P/S Ratio of 2.4. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is lower than Biofrontera AG P/B Ratio of 4.23. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Biofrontera AG P/FCF Ratio of -5.53. ROE: Harrow Health’s ROE of -0.21 is lower than Biofrontera AG ROE of -0.95. ROA: Harrow Health’s ROA of -0.03 is lower than Biofrontera AG ROA of -0.24. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Biofrontera AG Return On Capital Employed of -0.32. Gross Profit Margin: Harrow Health’s Gross Profit Margin of 0.67 is lower than Biofrontera AG Gross Profit Margin of 0.87. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Biofrontera AG Assets (Total) of 56.39M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Biofrontera AG Debt (Total) of 23.875M. Harrow Health vs Kamada Market Cap: Harrow Health’s Market Cap of 189217696 is lower than Kamada Market Cap of 209666336. Average Volume: Harrow Health’s Average Volume of 128163.0 is lower than Kamada Average Volume of 15760.0. Beta: Harrow Health’s Beta of 0.9 is higher than Kamada Beta of 0.23. Revenue: Harrow Health’s Revenue of 72476.0 is higher than Kamada Revenue of 103.642M. Net Income: Harrow Health’s Net Income of -17741.0 is lower than Kamada Net Income of -2.23M. Gross Profit: Harrow Health’s Gross Profit of 54262.0 is higher than Kamada Gross Profit of 30.328M. Ebitda: Harrow Health’s Ebitda of -23310.0 is lower than Kamada Ebitda of 5.001M. P/E Ratio: Harrow Health’s P/E Ratio of -71.31 is higher than Kamada P/E Ratio of -31.71. P/S Ratio: Harrow Health’s P/S Ratio of 28.24 is higher than Kamada P/S Ratio of 2.0. P/B Ratio: Harrow Health’s P/B Ratio of 18.89 is higher than Kamada P/B Ratio of 1.22. P/FCF Ratio: Harrow Health’s P/FCF Ratio of 78.72 is higher than Kamada P/FCF Ratio of -22.35. ROE: Harrow Health’s ROE of -0.21 is higher than Kamada ROE of -0.04. ROA: Harrow Health’s ROA of -0.03 is higher than Kamada ROA of -0.02. Return On Capital Employed: Harrow Health’s Return On Capital Employed of 0.01 is higher than Kamada Return On Capital Employed of -0.01. Gross Profit Margin: Harrow Health’s Gross Profit Margin of 0.67 is higher than Kamada Gross Profit Margin of 0.31. Assets (Total): Harrow Health’s Assets (Total) of 98329.0 is higher than Kamada Assets (Total) of 318.667M. Debt (Total): Harrow Health’s Debt (Total) of 77666.0 is higher than Kamada Debt (Total) of 42.338M. Shareholders Equity: Harrow Health’s Shareholders Equity of 10931.0 is lower than Kamada Shareholders Equity of 176.824M. About Harrow Health Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. the company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business, and DEXYCU, a treatment for post-operative inflammation. the company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of proprietary non-intravenous, sedative and anesthesia therapeutics for human medical procedures in hospital, outpatient and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company engaged in developing and commercialization of drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was previously known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 2006 and has its headquarters in San Diego, California.

How long Period I Can Choose to Pay My Short Term Loans Direct Lender Back?

Easy Ways to Fix QuickBooks Error 1904 (UPDATED Solution 2022)